Democratic congressional leaders in January 2007 plan to approve a bill similar to a measure (HR 810) President Bush vetoed earlier this year that would have expanded federal funding for human embryonic stem cell research, the AP/Houston Chronicle reports (Kellman, AP/Houston Chronicle, 11/29). Federal funding for embryonic stem cell research is allowed only for research using embryonic stem cell lines created on or before Aug. 9, 2001, under a policy announced by Bush on that date. Bush in July vetoed the Stem Cell Research Enhancement Act of 2005, which would have expanded stem cell lines that are eligible for federal funding and allowed funding for research using stem cells derived from embryos originally created for fertility treatments and willingly donated by patients. Congress lacked the two-thirds majority necessary to override Bush's veto. According to House Speaker-elect Nancy Pelosi (D-Calif.), the addition of six Democrats in the Senate and 29 in the House likely would not be enough to override another Bush veto on the legislation but added that Democrats aim to "build public support for a signature" (Kaiser Daily Women's Health Policy Report, 11/10). The midterm election revealed "that there's a mandate to expand embryonic stem cell research," Rep. Diana DeGette (D-Colo.), co-sponsor of the Stem Cell Research Enhancement Act, said on Tuesday, adding, "The public realizes the potential benefits, and what that does is [it] puts tremendous pressure on the White House." Tony Fratto, a White House spokesperson, said that Bush's position on the issue has not changed and that Bush would not "issue veto threats on hypothetical legislation." Pelosi has said the measure will be voted on during the first 100 business hours of the next congressional session, which begins in January 2007, and the Senate could vote on the measure before the end of January, according to the AP/Chronicle. "We are going to move it fairly quickly," Senate Majority Leader-elect Harry Reid (D-Nev.) said (AP/Houston Chronicle, 11/29).
"Reprinted with permission from kaisernetwork. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
вторник, 29 ноября 2011 г.
вторник, 22 ноября 2011 г.
Canadians Without Risk Factors Need Bone Density Measurements Only Once Every 5 Years According To Largest Ever Canadian Study On Osteoporosis
Dr David Goltzman and his team from the Research Institute of the McGill University Health Centre (RI MUHC) and McGill University - along with colleagues from across Canada - have issued new recommendations to public health authorities about how to best cope with osteoporosis, a bone disease which leads to increased risk of fracture, particularly in the elderly. Their recommendations derive from the latest results of the Canadian Multicentre Osteoporosis Study (CaMos), published in the Canadian Medical Association Journal (CMAJ).
Osteoporosis results from reduced bone mineral density (BMD), disrupted bone microarchitecture and alteration in the distribution and variety of non-collagenous proteins in bone, all of which serve to place sufferers at far greater risk of bone fractures, which can be life-threatening in the elderly. The measure of BMD is the main predictive marker of the disease.
"Osteoporosis has enormous impact on public health and on the quality of life of patients," Dr. Goltzman said.
The latest CaMos results confirm that, for women, menopause is a critical period during which bone mineral density decreases in all the bones studied. More specifically: an average decrease of 6.8% over 5 years was observed in the hip. Significant BMD loss also occurs after age 70, mainly in the hip bone. In men, BMD decreases more gradually, although it starts earlier, around the age of 40.
The fact that rapid BMD loss occurs after menopause was already known but had never been previously quantified, while the second period of BMD decline after age 70 is a completely new discovery.
"These findings provide new insight into the public health impact of osteoporosis," Dr. Goltzman explained. "Population aging combined with the potential human and financial consequences of fractures, notably hip fractures represent a major challenge. However, knowing the age at which bone loss is more likely to occur opens up new avenues for preventive measures."
The CaMos study involves nine other centres across Canada that are coordinated from the MUHC in Montreal. It has recruited more than 10,000 participants since 1996. The long duration and the national scale of the project have enabled researchers to determine that participants' BMD varies very slowly in the absence of other risk factors.
"The scope of the CaMos study means that we can produce data that are representative of the entire Canadian population, in order to help improve official recommendations, and to enhance the prevention, diagnosis and treatment of osteoporosis," said Dr Goltzman.
"In light of our results, we think that, in the absence of other risk factors, BMD should be measured every five years, instead of every two years, as is currently the case," he continued. "Of course, this frequency should be modified if the person does have other risk factors.
Dr. David Goltzman is the co-principal investigator of the CaMos project. He is a researcher in the Musculoskeletal Disorders axis at the RI MUHC and Professor of Medicine (Endocrinology/Metabolism) and of Physiology at McGill University's Faculty of Medicine.
The CaMos study is sponsored by the Canadian Institutes of Health Research (CIHR), Merck Frosst Canada Ltd., Eli Lilly Canada Inc., Novartis Pharmaceuticals Inc., the Alliance for Better Bone Health (Sanofi-Aventis and Procter & Gamble Pharmaceuticals Canada Inc.), the Dairy Farmers of Canada and the Arthritis Society of Canada.
About the Canadian Multicentre Osteoporosis Study (CaMos)
Initiated in 1996, CaMos is a prospective, population-based epidemiologic study involving a collaboration of leading Canadian experts, 10 study centres in 7 provinces and more than 10,000 participants across Canada. This largest ever Canadian study on osteoporosis, recognized internationally for its validity and quality, features a sample representative of the Canadian population and a long-term perspective with almost 70% retention after 10 years of follow-up. Study results have helped to inform health policy and improve osteoporosis prevention, diagnosis, and treatment in Canada. For more information on CaMos please visit camos/.
The McGill University Health Centre (MUHC) is a comprehensive academic health institution with an international reputation for excellence in clinical programs, research and teaching. Its partner hospitals are the Montreal Children's Hospital, the Montreal General Hospital, the Royal Victoria Hospital, the Montreal Neurological Hospital, the Montreal Chest Institute and the Lachine Hospital. The goal of the MUHC is to provide patient care based on the most advanced knowledge in the health care field and to contribute to the development of new knowledge.muhc/
The Research Institute of the McGill University Health Centre (RI MUHC) is a world-renowned biomedical and health-care hospital research centre. Located in Montreal, Quebec, the institute is the research arm of the MUHC, the university health center affiliated with the Faculty of Medicine at McGill University. The institute supports over 600 researchers, nearly 1200 graduate and post-doctoral students and operates more than 300 laboratories devoted to a broad spectrum of fundamental and clinical research. The Research Institute operates at the forefront of knowledge, innovation and technology and is inextricably linked to the clinical programs of the MUHC, ensuring that patients benefit directly from the latest research-based knowledge.
The Research Institute of the MUHC is supported in part by the Fonds de la recherche en sant?© du Qu?©bec.
For further details visit: muhc/research.
Source: Isabelle Kling
McGill University Health Centre
Osteoporosis results from reduced bone mineral density (BMD), disrupted bone microarchitecture and alteration in the distribution and variety of non-collagenous proteins in bone, all of which serve to place sufferers at far greater risk of bone fractures, which can be life-threatening in the elderly. The measure of BMD is the main predictive marker of the disease.
"Osteoporosis has enormous impact on public health and on the quality of life of patients," Dr. Goltzman said.
The latest CaMos results confirm that, for women, menopause is a critical period during which bone mineral density decreases in all the bones studied. More specifically: an average decrease of 6.8% over 5 years was observed in the hip. Significant BMD loss also occurs after age 70, mainly in the hip bone. In men, BMD decreases more gradually, although it starts earlier, around the age of 40.
The fact that rapid BMD loss occurs after menopause was already known but had never been previously quantified, while the second period of BMD decline after age 70 is a completely new discovery.
"These findings provide new insight into the public health impact of osteoporosis," Dr. Goltzman explained. "Population aging combined with the potential human and financial consequences of fractures, notably hip fractures represent a major challenge. However, knowing the age at which bone loss is more likely to occur opens up new avenues for preventive measures."
The CaMos study involves nine other centres across Canada that are coordinated from the MUHC in Montreal. It has recruited more than 10,000 participants since 1996. The long duration and the national scale of the project have enabled researchers to determine that participants' BMD varies very slowly in the absence of other risk factors.
"The scope of the CaMos study means that we can produce data that are representative of the entire Canadian population, in order to help improve official recommendations, and to enhance the prevention, diagnosis and treatment of osteoporosis," said Dr Goltzman.
"In light of our results, we think that, in the absence of other risk factors, BMD should be measured every five years, instead of every two years, as is currently the case," he continued. "Of course, this frequency should be modified if the person does have other risk factors.
Dr. David Goltzman is the co-principal investigator of the CaMos project. He is a researcher in the Musculoskeletal Disorders axis at the RI MUHC and Professor of Medicine (Endocrinology/Metabolism) and of Physiology at McGill University's Faculty of Medicine.
The CaMos study is sponsored by the Canadian Institutes of Health Research (CIHR), Merck Frosst Canada Ltd., Eli Lilly Canada Inc., Novartis Pharmaceuticals Inc., the Alliance for Better Bone Health (Sanofi-Aventis and Procter & Gamble Pharmaceuticals Canada Inc.), the Dairy Farmers of Canada and the Arthritis Society of Canada.
About the Canadian Multicentre Osteoporosis Study (CaMos)
Initiated in 1996, CaMos is a prospective, population-based epidemiologic study involving a collaboration of leading Canadian experts, 10 study centres in 7 provinces and more than 10,000 participants across Canada. This largest ever Canadian study on osteoporosis, recognized internationally for its validity and quality, features a sample representative of the Canadian population and a long-term perspective with almost 70% retention after 10 years of follow-up. Study results have helped to inform health policy and improve osteoporosis prevention, diagnosis, and treatment in Canada. For more information on CaMos please visit camos/.
The McGill University Health Centre (MUHC) is a comprehensive academic health institution with an international reputation for excellence in clinical programs, research and teaching. Its partner hospitals are the Montreal Children's Hospital, the Montreal General Hospital, the Royal Victoria Hospital, the Montreal Neurological Hospital, the Montreal Chest Institute and the Lachine Hospital. The goal of the MUHC is to provide patient care based on the most advanced knowledge in the health care field and to contribute to the development of new knowledge.muhc/
The Research Institute of the McGill University Health Centre (RI MUHC) is a world-renowned biomedical and health-care hospital research centre. Located in Montreal, Quebec, the institute is the research arm of the MUHC, the university health center affiliated with the Faculty of Medicine at McGill University. The institute supports over 600 researchers, nearly 1200 graduate and post-doctoral students and operates more than 300 laboratories devoted to a broad spectrum of fundamental and clinical research. The Research Institute operates at the forefront of knowledge, innovation and technology and is inextricably linked to the clinical programs of the MUHC, ensuring that patients benefit directly from the latest research-based knowledge.
The Research Institute of the MUHC is supported in part by the Fonds de la recherche en sant?© du Qu?©bec.
For further details visit: muhc/research.
Source: Isabelle Kling
McGill University Health Centre
вторник, 15 ноября 2011 г.
Hormone Therapy And Breast Pain Linked With Breast Cancer
Breast discomfort during hormone therapy may indicate increased risk for breast cancer
FINDINGS: It is known that postmenopausal women taking estrogen plus progestin in hormone replacement therapy experience both increased breast density and breast discomfort. The researchers sought to determine whether the discomfort was a signal for increased density. Using data from women enrolled in the Postmenopausal Estrogen/Progestin Interventions Mammographic Density study, they found that women with new-onset breast discomfort showed a 3.9 percent increase in breast density, compared with a 0.6 percent density increase in women who did not experience discomfort.
IMPACT: Women with dense tissue in more than 75 percent of the breast face four times the risk of developing breast cancer than do women who have little or no dense breast tissue. Thus, new-onset breast discomfort during hormone replacement therapy may indicate an increased risk for developing breast cancer.
AUTHORS: Carolyn J. Crandall, Arun Karlamangla, Mei-Hua Huang, Min Guan and Gail Greendale of UCLA; Giske Ursin of USC and the University of Oslo.
JOURNAL: Archives of Internal Medicine, Aug. 14-28 issue. The article can be viewed online at archinte.ama-assn/content/vol166/issue15/index.dtl.
FUNDERS: The California Breast Cancer Research Program, the National Institute on Aging and the National Institutes of Health.
Contact: Enrique Rivero
University of California - Los Angeles
FINDINGS: It is known that postmenopausal women taking estrogen plus progestin in hormone replacement therapy experience both increased breast density and breast discomfort. The researchers sought to determine whether the discomfort was a signal for increased density. Using data from women enrolled in the Postmenopausal Estrogen/Progestin Interventions Mammographic Density study, they found that women with new-onset breast discomfort showed a 3.9 percent increase in breast density, compared with a 0.6 percent density increase in women who did not experience discomfort.
IMPACT: Women with dense tissue in more than 75 percent of the breast face four times the risk of developing breast cancer than do women who have little or no dense breast tissue. Thus, new-onset breast discomfort during hormone replacement therapy may indicate an increased risk for developing breast cancer.
AUTHORS: Carolyn J. Crandall, Arun Karlamangla, Mei-Hua Huang, Min Guan and Gail Greendale of UCLA; Giske Ursin of USC and the University of Oslo.
JOURNAL: Archives of Internal Medicine, Aug. 14-28 issue. The article can be viewed online at archinte.ama-assn/content/vol166/issue15/index.dtl.
FUNDERS: The California Breast Cancer Research Program, the National Institute on Aging and the National Institutes of Health.
Contact: Enrique Rivero
University of California - Los Angeles
вторник, 8 ноября 2011 г.
Chilean Appeals Court Panel Overturns Ruling Suspending Government Plan To Distribute EC At No Cost To Girls Ages 14 And Older
A panel of the Santiago, Chile, Appeals Court on Thursday overturned a temporary injunction issued by the court earlier this month that suspended the government's plan to distribute emergency contraceptive pills in public clinics to girls ages 14 and older at no cost and without parental consent Reuters AlertNet reports (Reuters AlertNet, 9/22). Chilean Health Minister Maria Soledad Barria earlier this month announced the government's plans to distribute EC, which can prevent pregnancy if taken up to 72 hours after sexual intercourse and since 2001 has been available in pharmacies in Chile by prescription. It also has been available to teenagers with parental consent. However, EC -- which costs about $20 in the country -- has been accessible only to the middle and upper classes, some people have said. Two parents and La Florida, Chile, Mayor Pablo Zalaquett filed lawsuits earlier this month seeking to block implementation of the law, according to Alejandro Espinoza, a spokesperson for Chile's Supreme Court (Kaiser Daily Women's Health Policy Report, 9/14). Zalaquett said that the panel's ruling to overturn the injunction is a "slap in the face to parents and families in Chile, and, unfortunately, the ones who will pay will be the poor and the country's youngest children." Government spokesperson Ricardo Lagos Weber said the panel's decision "seems correct" and "equitable," adding that the decision "obligates [the government] to take responsibility for the profound and serious reality that the sexual initiation of young people in Chile is occurring at a very early age" (Reuters AlertNet, 9/22). Rulings on the lawsuits challenging the government's plan could be issued in the next two to three weeks, according to court sources (EFE News Service, 9/22). Chilean Appeals Court Panel Overturns Ruling Suspending Government Plan To Distribute EC at No Cost to Girls Ages 14 and Older
[Sep 26, 2006]
[Sep 26, 2006]
A panel of the Santiago, Chile, Appeals Court on Thursday overturned a temporary injunction issued by the court earlier this month that suspended the government's plan to distribute emergency contraceptive pills in public clinics to girls ages 14 and older at no cost and without parental consent Reuters AlertNet reports (Reuters AlertNet, 9/22). Chilean Health Minister Maria Soledad Barria earlier this month announced the government's plans to distribute EC, which can prevent pregnancy if taken up to 72 hours after sexual intercourse and since 2001 has been available in pharmacies in Chile by prescription. It also has been available to teenagers with parental consent. However, EC -- which costs about $20 in the country -- has been accessible only to the middle and upper classes, some people have said. Two parents and La Florida, Chile, Mayor Pablo Zalaquett filed lawsuits earlier this month seeking to block implementation of the law, according to Alejandro Espinoza, a spokesperson for Chile's Supreme Court (Kaiser Daily Women's Health Policy Report, 9/14). Zalaquett said that the panel's ruling to overturn the injunction is a "slap in the face to parents and families in Chile, and, unfortunately, the ones who will pay will be the poor and the country's youngest children." Government spokesperson Ricardo Lagos Weber said the panel's decision "seems correct" and "equitable," adding that the decision "obligates [the government] to take responsibility for the profound and serious reality that the sexual initiation of young people in Chile is occurring at a very early age" (Reuters AlertNet, 9/22). Rulings on the lawsuits challenging the government's plan could be issued in the next two to three weeks, according to court sources (EFE News Service, 9/22).
"Reprinted with permission from kaisernetwork. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
вторник, 1 ноября 2011 г.
Brava System Used In New Study 'Breast Augmentation With Grafting Of Liposuctioned Fat: A Safe And Effective Procedure'
The Brava System, the only clinically
proven device for non-surgical breast augmentation, is part of a leading
edge study that offers women a new minimally invasive option for breast
augmentation and reconstruction. The study, "Breast Augmentation With
Grafting of Liposuctioned Fat: A Safe and Effective Procedure," is being
conducted by Roger K. Khouri, M.D., Steven E. Chavoustie, M.D. and Macarena
Carretero, M.D. The preliminary findings will be presented today at the
American College of Obstetricians and Gynecologists (ACOG) 55th Annual
Clinical Meeting in San Diego. Until now, women have had two
clinically-proven options available for breast augmentation: surgical
breast implants and a non-surgical enhancement through the use of an
external tissue expansion device. In this study, physicians utilize
autologous fat to reshape and augment the breasts.
Historically, autologous fat injection in breast augmentation was
controversial and banned in 1987 by the American Society of Plastic and
Reconstructive Surgeon's Ad-Hoc Committee on New Procedures. The
Committee's opinion stipulated that much of the injected fat would not
survive and the physiologic response to fat necrosis was scarring and
calcification, thus making mammography difficult to interpret. Today, with
advancements in breast imaging, the harvesting of tissue, more refined
surgical cannulas and improved preparation of the recipient graft site,
this procedure is now a viable option for breast augmentation. For this
procedure, patients are treated pre-operatively and post-operatively using
Brava, an external tissue expander, to prepare, and later stent, the
recipient site. The single-stage, large-volume lipotransfer breast
augmentation notes a graft survival rate of 90% in the prepared, expanded,
hypervascularized tissue bed. While the study is on-going, the 25 reported
patients who have gone through the process have had increases of between 90
to 300 ml per breast (approximately 1 to 2-1/2 cup sizes). "OB/GYNs are
frequently asked by their patients about breast augmentation and
reconstruction", says Dr. Chavoustie. "Traditionally, there were only two
alternatives we could offer our patients, breast implant surgery or a
non-surgical breast expansion device. Now, this new procedure, which is
both safe and effective, offers the benefit of a natural (autologous) fat
filler, which will not affect breast imaging, and has the added benefit of
target site liposuctioning. Dr. Chavoustie goes on to explain, "Not only
are we looking at this new cutting edge procedure as a cosmetic
alternative, but also for future reconstructive applications for patients
with status-post lumpectomy filling defects or breast asymmetry."
Dr. Steven Chavoustie, Physician Director of Research and Development
at Brava, LLC, will be present at the ACOG's Annual Clinical Meeting,
Poster Presentation #98, to discuss the study in more detail on Tuesday
afternoon, May 8th. He will also be available at booth #436 (Brava, LLC)
Monday, May 7th and Wednesday, May 9th.
For more information about the Brava System, please visit the Brava Web
site, brava.
About the Study Investigators
Roger K. Khouri, M.D., is a noted plastic and reconstructive surgeon
practicing in Miami, FL and the inventor of the Brava System. Prior to
co-founding Brava, LLC, Dr. Khouri held professional and fellowship
positions at Brown, Harvard, New York and Washington Universities.
Steven E. Chavoustie, M.D., FACOG, is the Physician Director of Medical
Research and Development at Brava, LLC and a Voluntary Assistant Professor
of Obstetrics and Gynecology and Medical Education at the University of
Miami, Miller School of Medicine.
Macarena Carretero, M.D., is a practicing radiologist and co-director
at the Breast Health Center in South Miami, FL, and has served over 20
years as a member of the American Society of Breast Disease.
About Brava, LLC
Brava, LLC, founded in 1999, is a medical device manufacturer. Products
include the Brava Breast Enhancement System. Brava, LLC headquarters are
located at 14221 S.W. 142nd Street, Miami, FL 33186.
Brava, LLC
brava
proven device for non-surgical breast augmentation, is part of a leading
edge study that offers women a new minimally invasive option for breast
augmentation and reconstruction. The study, "Breast Augmentation With
Grafting of Liposuctioned Fat: A Safe and Effective Procedure," is being
conducted by Roger K. Khouri, M.D., Steven E. Chavoustie, M.D. and Macarena
Carretero, M.D. The preliminary findings will be presented today at the
American College of Obstetricians and Gynecologists (ACOG) 55th Annual
Clinical Meeting in San Diego. Until now, women have had two
clinically-proven options available for breast augmentation: surgical
breast implants and a non-surgical enhancement through the use of an
external tissue expansion device. In this study, physicians utilize
autologous fat to reshape and augment the breasts.
Historically, autologous fat injection in breast augmentation was
controversial and banned in 1987 by the American Society of Plastic and
Reconstructive Surgeon's Ad-Hoc Committee on New Procedures. The
Committee's opinion stipulated that much of the injected fat would not
survive and the physiologic response to fat necrosis was scarring and
calcification, thus making mammography difficult to interpret. Today, with
advancements in breast imaging, the harvesting of tissue, more refined
surgical cannulas and improved preparation of the recipient graft site,
this procedure is now a viable option for breast augmentation. For this
procedure, patients are treated pre-operatively and post-operatively using
Brava, an external tissue expander, to prepare, and later stent, the
recipient site. The single-stage, large-volume lipotransfer breast
augmentation notes a graft survival rate of 90% in the prepared, expanded,
hypervascularized tissue bed. While the study is on-going, the 25 reported
patients who have gone through the process have had increases of between 90
to 300 ml per breast (approximately 1 to 2-1/2 cup sizes). "OB/GYNs are
frequently asked by their patients about breast augmentation and
reconstruction", says Dr. Chavoustie. "Traditionally, there were only two
alternatives we could offer our patients, breast implant surgery or a
non-surgical breast expansion device. Now, this new procedure, which is
both safe and effective, offers the benefit of a natural (autologous) fat
filler, which will not affect breast imaging, and has the added benefit of
target site liposuctioning. Dr. Chavoustie goes on to explain, "Not only
are we looking at this new cutting edge procedure as a cosmetic
alternative, but also for future reconstructive applications for patients
with status-post lumpectomy filling defects or breast asymmetry."
Dr. Steven Chavoustie, Physician Director of Research and Development
at Brava, LLC, will be present at the ACOG's Annual Clinical Meeting,
Poster Presentation #98, to discuss the study in more detail on Tuesday
afternoon, May 8th. He will also be available at booth #436 (Brava, LLC)
Monday, May 7th and Wednesday, May 9th.
For more information about the Brava System, please visit the Brava Web
site, brava.
About the Study Investigators
Roger K. Khouri, M.D., is a noted plastic and reconstructive surgeon
practicing in Miami, FL and the inventor of the Brava System. Prior to
co-founding Brava, LLC, Dr. Khouri held professional and fellowship
positions at Brown, Harvard, New York and Washington Universities.
Steven E. Chavoustie, M.D., FACOG, is the Physician Director of Medical
Research and Development at Brava, LLC and a Voluntary Assistant Professor
of Obstetrics and Gynecology and Medical Education at the University of
Miami, Miller School of Medicine.
Macarena Carretero, M.D., is a practicing radiologist and co-director
at the Breast Health Center in South Miami, FL, and has served over 20
years as a member of the American Society of Breast Disease.
About Brava, LLC
Brava, LLC, founded in 1999, is a medical device manufacturer. Products
include the Brava Breast Enhancement System. Brava, LLC headquarters are
located at 14221 S.W. 142nd Street, Miami, FL 33186.
Brava, LLC
brava
Подписаться на:
Комментарии (Atom)